<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010499</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU R 143/2021</org_study_id>
    <nct_id>NCT05010499</nct_id>
  </id_info>
  <brief_title>Hip Arthroscopy; Femoral Nerve Block or Fascia Iliaca Block</brief_title>
  <official_title>Hip Arthroscopy; Femoral Nerve Block or Fascia Iliaca Block: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing hip arthroscopy will be divided into 2 groups after receiving general&#xD;
      anesthesia. 1 group will receive femoral nerve block and the other one will receive fascia&#xD;
      iliaca block. Postoperative total rescue analgesia will recorded in both groups, and in which&#xD;
      group early ambulation will take place .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing hip arthaoscope will be conducted to operating room, where standard&#xD;
      intraoperative monitoring will be applied, pulse oximetry, 5 lead ECG then peripheral&#xD;
      cannulation. Anesthesia will be induced with fentanyl 1.5Î¼g/kg, midazolam 0.1-0.5 mg/kg,&#xD;
      cis-atracurium 0.15 mg/kg followed by intubation. Then anesthesia will be maintained with&#xD;
      isoflurane1-1.5% Patients will be divided into two groups according to the randomization&#xD;
      envelopes:&#xD;
&#xD;
      Group (A) :( 15 patients) the fascia iliaca block: Patient in the supine position, skin will&#xD;
      be disinfected and linear transducer (8-12 MHZ) will be positioned to identify the femoral&#xD;
      artery and the iliopsoas muscle and fascia iliaca. The transducer will be moved laterally&#xD;
      until the sartorius muscle is identified. Echogenic needle (Bajunk, 80 m.m length) will be&#xD;
      inserted in-plane, as it will pass through fascia iliaca, the fascia will be first seen&#xD;
      indented by the needle. While piercing the fascia, a &quot;pop&quot; may be felt, and the fascia may be&#xD;
      seen to &quot;snap&quot; back on the US image (SONOSITE). After negative aspiration, 1-2 mL of local&#xD;
      anesthetic is injected to confirm the proper injection plane between the fascia and the&#xD;
      iliopsoas muscle. A proper injection will result in the separation of the fascia iliaca by&#xD;
      the local anesthetic in the medial-lateral direction from the point of injection as&#xD;
      described. Releasing the pressure of the transducer may reduce the resistance to injection&#xD;
      and improve the distribution of local anesthetic. If the spread is deemed inadequate,&#xD;
      additional injections laterally or medially to the original needle insertion or injection can&#xD;
      be made to facilitate the medial-lateral spread (the injection is stopped and the needle&#xD;
      repositioned before continuing. Additional injections may be made to ensure adequate spread)&#xD;
      (Yun MJ, et al., 2009). 40 mL of 0.25% levobupivacaine will be given. The success of the&#xD;
      nerve block is best predicted by documenting the spread of local anesthetic toward the&#xD;
      femoral nerve medially and underneath the sartorius muscle laterally (L. Hanna, et al.,&#xD;
      2014).&#xD;
&#xD;
      Group (B): Control group, (15 patients) femoral nerve block: With the patient in the supine&#xD;
      position, the skin over the femoral crease will be disinfected and the transducer will be&#xD;
      positioned to identify the femoral artery and nerve. If the nerve is not immediately apparent&#xD;
      lateral to the artery, tilting the transducer proximally or distally often helps to image and&#xD;
      highlight the nerve from the iliacus muscle and the more superficial adipose tissue. Once the&#xD;
      femoral nerve is identified, the needle will be inserted in-plane in a lateral to medial&#xD;
      orientation and advanced toward the femoral nerve (Mariano E.R ,et al., 2013). Once the&#xD;
      needle tip is adjacent (either above, below, or lateral) to the nerve, and after careful&#xD;
      aspiration, 1-2 mL of local anesthetic will be injected to confirm proper needle placement&#xD;
      that will push the femoral nerve away from the injection followed by total volume of 20 ml&#xD;
      0.25% levobupivacaine (Lamaroon A. et al., 2014) The blocks will be performed by the expert&#xD;
      anesthesia staff, and then positioning of patients will be done for the hip arthroscopy.&#xD;
      Another blinded doctor to the type of block received will attend the surgery and manage and&#xD;
      record any additional intraoperative analgesic requirements.&#xD;
&#xD;
      Postoperatively, timing for the first rescue analgesia will be recorded, if VAS is more than&#xD;
      5, 25 mg pethidine will be given. If no improvement second rescue analgesia in form 5 mg&#xD;
      morphine will be given .Also total narcotics demand will be recorded with measurement of&#xD;
      (VAS) hourly in the first 4 hours postoperatively then every 4 hours for 8 hours .Early&#xD;
      ambulation will be assessed and recorded together with assessing the weakness of quadriceps&#xD;
      femoris.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients undergoing hip arthroscope are divided into 2 groups. patients either receive femoral nerve block or fascia iliaca block.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>neither the patients nor the treating doctor know the type of block patient received.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Record the time patients require analgesia postoperatively</measure>
    <time_frame>12 hours</time_frame>
    <description>Assessment of postoperative pain score by Visual analogue Scale (VAS) and the time of demand for first rescue analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative ability to ambulate.</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Assess the time patients start to ambulate postoperative.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anlgesia for Hip Arthroscopy by Assessing Quality of Different Type of Regional Block, Femoral Nerve Block Versus Fascia Iliaca Block</condition>
  <arm_group>
    <arm_group_label>Femoral nerve block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive femoral nerve block (20 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fascia iliaca block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive fascia iliaca block (40 ml levobupivacaine 0.25%) after general anesthesia for hip arthroscpe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>femoral nerve block receives 20 ml of levobupivacaine 0.25%</description>
    <arm_group_label>Femoral nerve block</arm_group_label>
    <other_name>Bupivacaine hydrochloride (Marcaine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>Fascia iliaca block receives 40 ml of levobupivacaine 0.25%</description>
    <arm_group_label>Fascia iliaca block</arm_group_label>
    <other_name>Bupivacaine Hydrochloride (Marcaine)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 21 and 45 years ,ASA I and II undergoing hip arthroscope.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 21 or more than 45 years&#xD;
&#xD;
          -  ASA IV&#xD;
&#xD;
          -  Those who have an emergency surgery, or patients scheduled for complicated surgeries&#xD;
&#xD;
          -  Those who have a history of allergy to levobupivacaine&#xD;
&#xD;
          -  local skin site infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>maha sadek El Derh</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>maha S El Derh, MD</last_name>
      <phone>01144866675</phone>
      <email>mahasadek81@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>mohamed Ali, MD</last_name>
      <phone>01006512101</phone>
      <email>mohmourad1980@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>maha sadek El Derh</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

